Author of

• 25922

  +

  P1.02 - Advocacy (Not CME Accredited Session) (ID 934)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall

  • 26385

    +

    P1.02-04 - The EGFR Resisters Lung Cancer Group: A Patient-Driven Initiative to Understand & Improve Treatments for EGFR+ Lung Cancer  (ID 12001)

    16:45 - 18:00  |  Presenting Author(s): Jill Feldman
    • Abstract
    • Slides

    Background
    

    Lung cancer patients harboring mutations in the EGFR gene represent a significant amount of patients diagnosed with non-small cell lung cancer (NSCLC). Approximately 10-15% of patients with NSCLC in the United States (U.S.) and 35% in Asia have an EGFR mutation. In the U.S., more than 20,000 people with EGFR-positive lung cancer are diagnosed each year.

    Although there has been an increase in progression-free survival in patients due to EGFR tyrosine kinase inhibitors (TKIs), patients eventually develop acquired resistance. With each generation of TKIs developed, more mechanisms of resistance are discovered; therefore the development of drugs to target resistance mutations and other mechanisms of resistance are desperately needed.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    The EGFR Resisters is a group of people living with and/or personally affected by EGFR-positive lung cancer. The purpose of founding the group is to build a community of survivors and caregivers to share knowledge, provide support, and confidentially collect patient data (such as patient demographics, details of lung cancer diagnosis, specific type of EGFR mutation, acquired resistance and mechanism of resistance). Patient data will be aggregated and analyzed to identify trends such as commonalities and differences in mechanisms of resistance.

    The goal of the EGFR Resisters is to improve outcomes for people with EGFR-positive lung cancer by accelerating research. Our ultimate objective is changing EGFR-positive lung cancer into a manageable chronic disease.

    4c3880bb027f159e801041b1021e88e8 Result
    

    EGFR Resisters is comprised of nearly 400 members from 20 countries. Out of the 60% of members who have provided data, 65% have already developed acquired resistance to their current EGFR TKI. The types of resistance mechanisms seen in this community are consistent with results that have been published from other studies.

    Since the launch of our website (www.egfrcancer.org) in February, we have been contacted by numerous stakeholders from academia, research and industry who are interested in collaborating with the EGFR Resisters to help further our goal.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    We are working to increase the size of our EGFR Resisters community with the assistance of advocacy groups and medical professionals. We are also building relationships with EGFR thought leaders in the scientific and medical community to identify practice gaps and develop an action plan for educational and research efforts. Our aim is to use the strength of our collaborations to drive important research questions and fund novel research and clinical trials.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.